S. 4698 is a bill that aims to modify the Federal Food, Drug, and Cosmetic Act to allow patients who are diagnosed with life-threatening diseases or severely debilitating illnesses to access investigational individualized medical treatments. This means that patients could potentially use experimental treatments that have not yet been fully approved by the FDA, giving them more options in desperate situations.
Supporters of S. 4698 have praised the bill for providing hope and increased treatment options for patients facing dire health situations. They argue that it empowers patients and doctors to make informed choices about experimental therapies that could potentially save lives.
Critics of S. 4698 have expressed concerns about the safety and efficacy of allowing access to unapproved treatments. They worry that this could lead to patients using ineffective or harmful therapies, and that it may undermine the rigorous FDA approval process designed to ensure public safety.
All donors are from Applied Materials, Inc., a company not directly related to the pharmaceutical or medical treatment industry. The risk of conflict of interest is low as the donors' industry does not directly benefit from the bill.
Top industries and organizations funding Ron Johnson, from FEC data.
Source: FEC campaign finance records
